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YOUNG, E A., J. M WALKER, R HOUGHTEN AND H AKIL. The degradatton ofdynorphm A m bram tt~sue m vlvo 
and m vitro. PEPTIDES 8(4) 701-707, 1987.--The demonstration of analgesia following m vtvo admlmstratlon of dynorphln 
A (Dyn A) has been difficult In contrast, a number of electrophyslologlcal and behaworal effects reported with m vtvo 
rejection of Dyn A can be produced by des-tyrosme dynorphm A (Dyn A 2-17). This suggested the extremely rapid amino 
terminal degradation of dynorphm A To test this hypothesis, we examined the degradation of dynorphm A following m 
vtvo rejection into the penaqueductal gray (PAG) as well as m vttro using rat brain membranes under receptor binding 
conditions. In vtvo, we observed the rapid amino terminal cleavage of tyrosme to yield the relatively more stable des- 
tyrosme dynorphm A This same cleavage after tyrosme was observed tn vttro. Inhibition of this amlnopeptldase actlwty tn 
vttro was observed by the ad&tlon of dynorphln A 2-17 or dynorphm A 7-17 but not after the addition of dynorphm A 1-13, 
dynorphm A 1-8, dynorphln B or a-neo-endorphm suggesting a specific enzyme may be responsible The detection of the 
behaviorally active des-tyrosme dynorphm A following m vtvo rejection ofdynorphm A suggests that this peptlde may play 
an important physiological role. 
Dynorphm A In vtvo In vttro Penaqueductal gray 
DYNORPHIN A has been shown to be an extremely potent 
opiold peptlde active at several opioid receptors in a number 
of m vitro preparations [4, 11, 16--19, 29, 43]. Despite the 
demonstratton of its high affinity binding to brain membrane 
receptors, and its substantml potency m guinea p~g deum 
preparations, demonstration of analgesia following m vlvo 
rejection has been difficult [13-15, 19, 27, 28, 38, 42]. A 
number of behavlorial and electrophysiological effects have 
been reported followmg in vivo injection of pharmacological 
doses ofdynorphm A [1, 2, 10, 19, 25, 27, 28, 35, 36, 38, 42]. 
With the exception of diuresis, the behavioral and physiolog- 
ical effects often appear to be non-oploid since they cannot 
be reversed by high doses of naloxone (10 mg/kg) or other 
opiate antagonists, and, these same effects can be produced 
by dynorphin A 2-13 or dynorphin A 2-17 [10, 28, 40, 42]. 
One explanation for the lack of potency of dynorphin A in 
tests of thermal pain stems from findings that kappa agonlsts 
are weak in tests of thermal pain [23]. However, the kappa 
opiold U-50488H was found to be active m the tail flick test 
after either systemic or intracerebroventncular injections m 
rats [37]. Early stu&es with another opioid peptide, 
enkephahn, showed slmdar difficulties demonstrating 
analgesia after m vtvo injection of pharmacological doses 
[3,9]. In the case of enkephalin, these difficulties resulted 
from extremely rapid breakdown of enkephalin following in 
vtvo injection [9, 12, 21, 22, 24, 33, 34]. The availability of 
stable analogues of enkephalin led to the demonstration of a 
variety of opioid effects with these compounds [6, 7, 26, 39, 
41]. However, in the case of dynorphin A, the stable 
analogues produced thus far have altered the receptor selec- 
twlty of dynorphin A, and thus changed the pharmacological 
profile of dynorphin A [5]. Smce suitable stable analogues 
are not available, it xs criUcal to examine the stability of 
dynorphm A following in vtvo injection and see if we could 
detect any fragments of dynorphin A that are known to be 
behaviorally active such as dynorphin A 2-17 or dynorphin 
A 1-8. 
Aside from concerns about the stability of dynorphin A 
following m vlvo injecUons, studies on the degradation of 
brain peptides and other neurotransmitters can yield impor- 
tant information. In the enkephahn system, despite the wide- 
spread presence of general amlnopeptidases that could use 
enkephalin as a substrate, in vtvo degradation stu&es 
demonstrated that a family of enzymes, the enkephalinases, 
were responsible for the in vivo breakdown [9, 12, 21, 22, 24, 
33, 34]. The existence of such specific degrading enzymes 
provides another regulatory stte in neurotransmitter sys- 
tems. Inhibitors of such specific enzymes can provide other 
strategies for studying neuronal regulation or for prolonging 
the actions of endogenous llgands released under physiolog- 
ical conditions ([31] and cf. monoamine oxidase mhlbitors). 
In addition to concerns about in vlvo breakdown of 
dynorphin A, breakdown of dynorphm A in in vitro systems 
can alter its pharmacological profile. During our own recep- 
701 
702 YOUNG, WALKER, HOUGHTEN AND AKIL 
tor binding studies, we became concerned about the rapid 
breakdown of this endogenous peptide in our membrane 
preparation. Since opioid binding activity is dependent upon 
an intact tyroslne at the N-terminal, it is particularly cntical 
to assure that the peptlde is stable under these conditions. 
Similar studies with CCK-33 binding have demonstrated 
breakdown under binding conditions that can be inhibited by 
bacltracln, yielding a 2-fold increase in specific binding [32]. 
Previous studies by Leslie and Goldsteln [20] in rat brain 
membrane preparations using [~25I] dynorphln A 1-13 had 
demonstrated extremely rapid NH~-termlnal cleavage of the 
tyrosine as well as rapid progressive COOH-termlnal 
shortening. Similarly, m vttro rat membrane data by Robson 
et al. [30] using dynorphln A 1-9 demonstrated that 
nonspeclfiC inhibition of the NH.,-terminal cleavage of 
tyroslne led to COOH-terminal shortening and formation of 
numerous other opioid-actlve dynorphln fragments, making 
true pharmacologic characterization of dynorphln A im- 
possible under these conditions Interestingly, the data from 
Leslie and Goldsteln [20] suggested the existence of a spe- 
cific membrane bound exopeptidase in rat brain that could be 
inhibited by COOH-terminal fragments of dynorphin A 1-13 
(dynorphin A 6-13), but only in concentrations that affected 
oplold binding. To explore these problems, we undertook (a) 
characterization of the time course of dynorphln breakdown 
m wvo and in vi tro,  (b) identification of products following in 
v m o  incubation with washed brain membranes, (c) charac- 
terization of the ability of dynorphin fragments and related 
peptides to inhibit the breakdown of [3H]dynorphin A, and 
(d) comparison of the m vitro date with m vivo studies of the 
breakdown of [3H]dynorphln A injected into the 
periaquaductal gray (PAG) 
METHOD 
T l ~ u e  Prepara t ton  
Rat and guinea pig brains minus the cerebellum were 
homogenized with a Brinkman polytron in 50 mM Tris buffer 
(pH 7.4 at 24°C) at a concentration of 50 mg tissue (wet 
weight) per ml of buffer. After a 40 minute 37°C incubation to 
dissociate bound ligands, the homogenates were centrifuged 
at 40,000 × g, then resuspended m 50 mM Tris at a concen- 
tration of 37.5 mg tlssue/ml. 
P r o d u c t  Iden t i f i ca t ion  
The ['~H]dynorphm A used for all these studies was syn- 
thesized by one of us (R.H.). For breakdown studies m vttro, 
1 nM [3H]dynorphin A in Tris buffer was incubated with 15 
mg tissue in microfuge tubes at 0°C for 30-90 minutes in the 
presence or absence of possible inhibitory peptldes. The pH 
of Tris at this temperature is 7.2 with no change over the time 
course of the incubation. These peptldes were added in a 10 
microliter volume dissolved in a 50'50 mixture (v/v) of 
methanol to 0.1 N HCI (MeOH:HC1). Bound ['~H]dynorphin 
A was separated from free [aH]dynorphln A by centrlfuga- 
tlon for 5 minutes at 4°C in a Beckman microfuge. 
Two methods of chromatography were employed, a rapid 
molecular seiving with a short Sephadex column, followed 
by more complete identification with reverse phase HPLC. 
The supernatant was applied to a 12 centimeter G-10 column 
equilibrated in 2 N acetic acid with 0.1W/o BSA for molecular 
sieving. Using MeOH:HCI as an eluant, fractions (0.5 ml) 
were collected directly into scintillation vials. [3H]dynorphin 
A, [3H]Leu-enkephalin and [3H]tyroslne were used as stand- 
ards This column reliably separates dynorphin A from 
dynorphln A 1-8 from Leu-enkephahn. However, it does not 
separate Leu-enkephahn from tyrosine. Dynorphln A 1-13 
co-migrates with dynorphln A on this column. The fractions 
were suspended in l0 ml of scintillation cocktail for aqueous 
samples and counted in a Beckman LS 9000 scintillation 
counter. The bound (tissue pellet) was also counted to calcu- 
late recovery of [3H]dynorphln A as well as to determine 
both specific and nonspeclfiC tissue binding by centrifuga- 
tlon. Dynorphln A (Dyn A), dynorphln A 2-17 (dT dynor- 
phln) and dynorphln A 7-17 were a generous gift of Dr. 
David Coy. Dynorphln A 1-8 and dynorphln A 1-13 were 
purchased from Peninsula (Belmont, CA) and c~- 
neo-endorphln was purchased from Bachem (Torrance, CA). 
For final identification of products, separation by re- 
verse phase HPLC was undertaken. Buffer A consisted of 
0.1% trlfluoroacetlc acid (TFA) in water with 0.05% 
trlethylamlne (TEA). Buffer B consisted of 0.1% TFA, 80c~ 
acetonltrlle, 19.9% water with 0 05°~ TEA. Beginning at 4% 
Buffer A, a 10-minute gradient rising to 12% B produced 
separation of Tyr, Tyr-Gly and Tyr-Gly-Gly fragments A 
5-minute gradient from 12% to 27% B was followed by a 
45-minute gradient between 27-38c~ buffer B which 
produced good separation of Leu-enkephahn, dynorphln A 
1-8 and dynorphln A For use in these breakdown experi- 
ments, the ['~H]dynorphin A was repurlfied on the HPLC so 
all radioactivity co-migrated w~th the dynorphin A standard 
This repurlfied [~H]dynorphln A was tested for opiate bind- 
Ing activity to further insure that it was ['~H]dynorphln A 
After 0, 15, 30, 60 and 90 minutes incubation of 1 nM 
['~H]dynorphln A with brain homogenates, the supernatant 
was lyophlhzed, resuspended in MeOH HCI and then 
applied to the HPLC for separation. To insure proper Iden- 
tification of dynorphln and dynorphin fragments, unlabelled 
peptide fragments and tyroslne were added as standards in 
each HPLC sample run, and the fractions were counted with 
a Beckman LS 9000 Scintillation Counter to determine 
whether radioactivity co-migrated with dynorphln A or other 
dynorphln fragments as monitored by UV (220 nm). Re- 
covery was monitored by quantltlfylng the radioactivity 
applied to column and the counts recovered For those 
studies In which dynorphln fragments were measured by 
radloimmunoassay, dynorphln A, dT dynorphln and dynor- 
phln A 1-8 were not added. To assess the elutlon profile of 
those standards, a calibration HPLC run followed the sample 
runs on each day 
In Vlvo Studtes  
For m vtvo studies, 25 ga stainless steel guide cannulae 
were implanted Into the perlaqueductal gray (PAG) using the 
coordinates 5 1 mm posterior to bregma, 0.5 mm lateral to 
midhne, with the guide cannulae inserted to a depth of 4.5 
mm (Nose + 0.5 mm tilt) (Pellegrlno, Pellegrlno and 
Cushman, 1971). Seven to 10 days following surgery, the 
animals received an injection of 0.1 nanomole of 
[3H]dynorphln A plus 0.9 nanomole of unlabelled dynorphln 
A through a 30 ga stainless steel needle extending 2 mm 
beyond the guide into the PAG. The Injection volume was 1 
mlcroliter administered over 1 minute. To minimize 
backflow, the needle remained in place for 30 seconds after 
the end of the rejection. After varying time periods (0, 2.5, 5 
and 10 minutes), the rats were decapitated, their brains 
rapidly removed, and using a stereotactic block, a 2 mm slice 
of the PAG and the area 2 mm immediately rostral to the 
PAG were dissected The cortex and collicuh were trimmed 
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TABLE 1 
BREAKDOWN OF I3H] DYNORPtt lN A AFTER 9tl MINUTE INCUBATION AT 0°C 
(SEPHADEX G-10 SEPARATION) 
1 /xM 1 p,M [aH]Dyn A 
Control Dyn A 1-17 dTDyn Standard 
Rat Brain 
[ ~H]Dynorphm A 23% 62% 
1-17 size 
[ ~H]Tyrosme 67c~ 32~ 
size  
Guinea P~g Brim 
[ ~HlDynorphm A 40% 70% 
1-17 size 
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FIG 1. In vi tro time course for the breakdown of [3H]dynorphIn A in 
double washed rat brain membranes After incubation, supernatant 
was analyzed by HPLC for co-mlgratmn of the radmact~vlty w~th 
dynorphm A, tyrosme or other dynorphm fragments as standards. 
Data are expressed as percent of total rad~oactwlty recovered 
from these regmns and then these regions were immediately 
homogenized in extraction buffer (3:1 acetone:0.2 N HCI). 
The time from decapitation to homogenization averaged 1.5 
minutes. After centrifugation, the supernatant was 
lyophlhzed, then resuspended in MeOH:HC1 for the HPLC 
separation and identification. The radioactivity recovered in 
the tissue averaged 10% of the infused counts. It is unclear if 
the low recovery m tissue occurred because of nonspeclfiC 
loss to the cannula or guide or because of diffusion of 
radioactivity from the site of injection. However, when we 
extracted the areas surrounding the dissected regions httle 
radioactivity was found. More than 95~ of the radloactiwty 
m the t~ssue was present in the supernatant after extraction. 
The extracted material was applied to HPLC in MeOH:HC[ 
and separated using the gradient described above. 
After HPLC, half of each fraction was counted for 
radioactivity. The total radioactivity recovered from the 
HPLC runs averaged 91)% of the material applied to the col- 
umn. To characterize the forms of dynorphin immunoreac- 
twlty present after m v~vo rejection, the other half of each 
fraction was radioimmunoassayed with a dynorphm A 
antibody raised m our laboratory to dynorphin A 1-17 [8]. 
This antibody is fully cross reactive with dynorphin A 2-17, 
but does not recognize dynorphm A 1-8 and is only 51)% 
cross reactive with dynorphln A 1-13. 
RESULTS 
In Vitro R e s u l t s  
Time course studies using single washed membranes with 
HPLC identification and quantitation demonstrated rapid 
degradation of dynorphin A following m v i t r o  incubation 
wnh brain homogenates. At the end of 60 minutes incubaUon 
only 23% of the dynorphm A is intact. In contrast, double 
washed membranes showed slower breakdown (Fig. 1). The 
HPLC separation ~dentified the major radioactive break- 
down fragment as [3H]tyrosme. The rest of radioactivity 
co-migrated w~th dynorphin A or Leu-enkephalin. 
Initial inhibitor studies were done following 90 minutes 
incubation at 0°C, the optimal time for [3H]dynorphin A bind- 
ing m brain homogenates. Table 1 shows the data from one 
experiment. Molecular sieving with G-10 columns was used 
to quantitate breakdown and inhibition by other peptides. 
Thus, after 90 minutes incubation at 0°C with rat mem- 
branes, only 23% of the radioactivity co-migrates with 
[3H]dynorphln A size material, while 67% of the radioactivity 
is [ZH]tyrosine size. In contrast, in guinea pig brain homoge- 
hates at 0°C, 40% of the radioactivity elutes with the 
[3H]dynorphm A standard, while only 50% of the radioactiv- 
ity is [3H]tyroslne size material. In both species, the addition 
of 1 mlcromolar unlabelled dynorphm A substantially in- 
hibits the breakdown of the [3Hldynorphln A. It should be 
noted, however, that even this high concentration of unla- 
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SIXTY MINUTES INCUBATION SEPHADEX 
G- 10 SEPARATION 
Number of % [~H]Dyn A %[~HlTyr % 
Inhibitor Rephcat~ons S~ze Size Inhibition 
None 17 23 + 05  69 _+ 0 9  0 
l / x M D y n A  15 50.6 + 1 6 408_+ 2 36 + 2 
1 0 / x M D y n A  3 63 _+ 6 7  26 + 5 3 52_+ 9 
1 /~M dT-Dyn A 1 62 28 51 
l / x M D y n A 7 - 1 7  3 39 _+ 32  54 _+ 1 7 20 + 4 
1 0 / x M D y n A 7 - 1 7  2 65 _+ 4 2  27 _+ 5 6  55 + 5 
I / x M N A c D y n A  2 43 _+ 4 2  495 + 2 1 26_+ 5 
10/xM Dyn A 1-13 4 35.8 + 7 6 56 +_ 13 6 17 _+ 10 
10p, M DynB 6 32 6_+ 4 7  61 _+ 4 1 13 + 6 
10p~Ma-neo-end 3 237 + 4 66 _+ 65  0_+ 5 
10/xMDyn 1-8 3 243 _+ 3 6  66 _+ 4 2 + 4 
To calculate % inhibition the following formula was 
100 - % Dyn A intact with inhibitor 
100 
used 
100 - % Dyn A intact w~thout inhibitor 
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FIG. 2. HPLC profile from time course m PAG, showing the dlssap- 
pearance of [3H]dynorphln A and the appearance of [3H]tyrosme 
Standards are marked with arrows A very small proportion of the 
radmactlwty co-migrates with Leu-enkephalin. Data are expressed 
as percent of total radloactlwty recovered. 
be l led  d y n o r p h m  A does  no t  total ly  p r e v e n t  the  b r e a k d o w n  
of  the  [aH]dynorph in  A in e i t he r  species•  
Us ing  the  same  mo lecu l a r  s ieving quan t l t a t lon ,  des-  
t y r o s m e  d y n o r p h l n  A (dT-Dyn  or  d y n o r p h l n  A 2-17)  appea r s  
to inhib i t  the  b r e a k d o w n  o f  [aH]dynorph in  A to the  same 
e x t e n t  as d y n o r p h l n  A in ra t  bra in .  This  is no t  the  case  in 
gu inea  pig bra in ,  whe re  d y n o r p h i n  A is more  ef fec t ive  at  
p r even t ing  b r e a k d o w n  of  [aH]dynorph ln  A than  is dT dynor -  
phin  Thus ,  there  a p p e a r  to be  species  d i f fe rences  in the  
a m m o p e p t i d a s e s  tha t  c leave  the  NH2- termina l  ty ros lne  f rom 
d y n o r p h m  A. The  abil i ty of  d y n o r p h l n  2-17 to b lock  the 
b r e a k d o w n  may  r ep re sen t  c lass ic  e n d - p r o d u c t  inhibi t ion 
t h rough  an  al loster ic  site, or,  a l t e rna t ive ly ,  it may  be tha t  the  
recogmtlon site for this dynorph in  ammopep t ldase  is depend-  
en t  upon  the non-op ia te  core  of  d y n o r p h l n .  C o n s e q u e n t l y  we 
exp lo red  the  effects  of  o the r  d y n o r p h i n  re la ted  pep t tdes  on  
the  b r e a k d o w n  of  [ aH]dynorphm A in ra t  b ra in  (Table  2). 
S ince  we w a n t e d  to min imize  the  b r e a k d o w n  o f  the  compe t -  
ing pept ides ,  we used a sho r t e r  incuba t ion  t ime of  60 minu te s  
at  0°C. 
Again  us ing molecu la r  s ieving quan t l t a t lon ,  it c an  be  seen  
in Table  2 tha t  the  non-op ia te  con ta in ing  s equence  of  dynor -  
p h m  A, d y n o r p h i n  A 7-17,  is able  to par t ia l ly  inhib i t  the  
b r e a k d o w n  of  [3H]dynorphIn A. It  is no t  as ef fec t ive  an  in- 
h ib i to r  as d y n o r p h i n  A o f  dT d y n o r p h l n ,  bu t  tt pose s se s  ap- 
p rox ima te ly  50% of  the  ac t iv i ty  of  d y n o r p h i n  A itself. W h e n  
the  c o n c e n t r a t i o n  is i nc reased  to 10/xM, d y n o r p h i n  A 7-17 
shows  s imilar  inhib i t ion  as 1 /xM d y n o r p h i n  A. D y n o r p h l n  A 
1-13, d y n o r p h i n  B and  a - n e o - e n d o r p h I n  show some  small  
inh ib i to ry  ac t ions  at  1 0 / x M  concen t r a t i on .  M e t - e n k e p h a l l n  
2-5,  a c lassic  e n k e p h a l i n a s e  inhibi tor ,  does  no t  affect  the  
b r e a k d o w n  (da ta  no t  shown) ,  no r  does  d y n o r p h i n  A 1-8, 
a n o t h e r  p r o d y n o r p h l n  de r ived  pept ide .  I f  a specif ic  e n z y m e  
exis ts ,  the  fai lure to d e m o n s t r a t e  inhib i t ion  by  d y n o r p h i n  A 
1-8 may  indica te  e i the r  a lack of  recogni t ion  of  this  pept ide  
or  tha t  d y n o r p h i n  A 1-8 is b r o k e n  down  so rapidly  tha t  by  60 
minu t e s  the re  is no  longer  any  " i n h i b i t o r "  left. Thus ,  s imilar  
s tudies  were  u n d e r t a k e n  at 30 minutes .  E v e n  af te r  30 min- 
u tes  i ncuba t ion  at 0°C, d y n o r p h i n  A 1-8 s h o w e d  no inhibi-  
t ion  of  the  amino  te rmina l  c leavage  of  ty ros ine  f rom dynor -  
ph in  A, w h e n  c o m p a r e d  to the  [3H]dynorphin  A b r e a k d o w n  
s t anda rd  for  t ha t  expe r imen t .  
In Vivo  R e , s u i t s  
Using  H P L C ,  m v t v o  b r e a k d o w n  was quan t l t a t ed  and 
DEGRADATION OF DYNORPHIN A 705 













n- y n o r p h m  A 





3H Leu-Enkephahn ,, 
O 25 5 7 5 10 
Twme (rain) 
FIG. 3. Summary graph of m vtvo time course As [3H]dynorphln 
disappears, [3H]tyrosme appears There is a shght accumulation of 
[~H]matenal that co-migrates with Leu-enkephahn. 
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FIG 4 Dynorphm radlolmmunoassay of HPLC separation demon- 
strates the formation of des-tyrosme dynorphm A (dT-Dyn) from 
dynorphm A (Dyn A). In both the area of m lectlon (PAG) and the 
region rostral to the PAG (frontal) dTdynorphm can be detected 
Standards are marked with arrows 
products were identified. In vtvo, the breakdown of 
[3H]dynorphin A proceeds extremely rapidly (Figs. 2 and 3). 
Thus, even ume 0 samples show less than 50% of the 
radioactivity co-migrating with dynorphin A on HPLC. The 
rest of the radsoactwity co-migrates with tyrosme. This 
aminotermmal cleavage of  tyrosme appears to be common to 
both m vitro and in vtvo preparations.  Since dT dynorphin 
has been shown to be biologically active, ~t was of interest to 
see if dT dynorphm was formed and stable following the loss 
of tyrosine from dynorphin. The results are m Fig. 4. Sub- 
stantial dT dynorphm can be demonstrated by radioim- 
munoassay.  In the area of injection (PAG) at the end of 10 
minutes, our longest time point, 84% of the dynorphin A-IR 
co-migrates wlth dT dynorphin. The total of  dT dynorphin- 
IR plus dynorphin A-IR equaled the amount rejected, 
suggesting that there is little loss of dynorphin A by conver- 
sion of dT dynorphin to other fragments that were not rec- 
ognized by our antibody. The ratio of  [aH]dynorphm A to 
[~H]tyroslne (80%:20%) is the same as the ratio of dynorphm 
A to dT dynorphin (84%:16%) in these same fractions. This 
suggests that injection of  dynorphin A is followed by rapid 
ammo terminal cleavage with the formation of  a relatively 
more stable compound, dT dynorphm. However ,  without a 
time course of dT dynorphin breakdown it is not possible to 
conclusively demonstrate the stabihty of  dT dynorphin m 
vivo.  But, at the 10 minute time point 5-6-fold more dT 
dynorphin then dynorphin A is present. 
DISCUSSION 
The difficulty in demonstrating [aH]dynorphm A binding 
to rat brain membranes suggested that the breakdown of 
[3H]dynorphln A was extremely rapid. Leslie and Goldstem 
had published similar findings with [lzsI]dynorphin A 1-13 
[20]. Our time course studies in vitro confirm this notion. In 
single washed membranes,  the breakdown proceeded very 
rapidly even at 0°C, resulting in less than 25% of the material 
intact at 30 minutes. In contrast,  using double washed mem- 
branes substantially slowed the breakdown of [3H]dynorphin 
A in vitro Therefore, the proteolytic enzymes may be 
loosely associated with the membranes,  suggesting 
nonspecific soluble enzymes may be involved in breakdown 
in vLtro. In all cases, the radiolabelled breakdown product  
appeared to be [3H]tyrosIne, without evidence of cleavage at 
the other sites such as between Gly-Gly or  Gly-Phe to yield 
Tyr-Gly or Tyr-Gly-Gly.  This suggests that enkephalinases 
are not the primary enzymes involved in the breakdown 
under these conditions. In the double washed membrane 
preparation, the continued co-migration on HPLC of 
[aH]dynorphin A with the unlabelled standard suggests that 
extensive carboxy terminal cleavage is not occurring under 
these conditions. This is in contrast  to the data of Leslie and 
Goldstein for dynorphin A 1-13 [20] and Robson et  al. [31] 
for dynorphin A 1-9, who found that carboxy terminal cleav- 
age proceeds at a rate similar to amino terminal cleavage. It 
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may  be tha t  the  na t ive  full s t ruc tu re  (Dyn A) 1s more  resis-  
t an t  to c a r b o x y - p e p t i d a s e  act iv i ty .  L ikewise ,  we were  un- 
able  to d e m o n s t r a t e  by  H P L C  any  [3H]dynorphin  A 1-8 size 
peaks  fol lowing m v i t r o  i ncuba t ion  or  m v t v o  reject ion,  
sugges t ing  c o n v e r s i o n  of  [ '~H]dynorphm A to smal le r  opmte  
a c t w e  fo rms  is no t  a ma jo r  p a t h w a y  of  deg rada t ion  In con-  
t ras t ,  we d~d o b s e r v e  a smal l  bu t  c o n s i s t e n t  peak  of  radioac-  
t iwty  tha t  co-migra tes  on  H P L C  w~th L e u - e n k e p h a l i n  and  
co-e lu tes  with  the  ty ros ine  on  G-10 s iewng co lumn.  Wi thou t  
a n o t h e r  sys tem for  ~dent~fication such  as th in  layer  ch roma-  
t og raphy  for  amino  acid s equence  we are unab le  to  conc lude  
t ha t  this  r ad ioac t ive  mater ia l  is L e u - e n k e p h a h n ,  howeve r ,  
au then t i c  L e u - e n k e p h a h n  would  be so rapidly degraded  
u n d e r  these  c~rcumstances  tha t  we would  not  expec t  to see 
L e u - e n k e p h a h n  [9, 33, 34]. S ince  we are unab le  to demon-  
s t ra te  [ '~H]Tyr-Gly-Gly fo rma t ion  tha t  would  be g e n e r a t e d  by  
the  b r e a k d o w n  of  [3H]Leu-enkepha l in ,  the  gene ra t i on  of  
L e u - e n k e p h a l i n  would  a p p e a r  to be a re la t ively  mino r  path-  
way tf at  occurs  at  all. 
A l though  the  a m m o p e p t t d a s e  c leavage  o f  t y r o s m e  could  
be  a c c o m p l i s h e d  by  a genera l  am i nopep t i da s e ,  the  m h i b t h o n  
of  this  ac t ion  by  dT d y n o r p h m  a n d  d y n o r p h m  A 7-17,  
suggests  there  may  be  a specif ic  e n z y m e  tha t  c leaves  dynor -  
ph in  A wi th  a recogni t ion  site m the  C O O H - t e r m l n a l  d o m a i n  
of  d y n o r p h i n  A. Th e  inhibi t ion  o f  this  amino  pep t idase  ac tw-  
tty by  a c o m p o u n d  wh ich  c a n n o t  func t ion  as a subs t r a t e  
( d y n o r p h i n  A 7-17)  suppor t s  a specif ic  e n z y m e  h y p o t h e s i s  
Similar  f indings  have  b e e n  r epo r t ed  for  d y n o r p h i n  A 6-13,  
~.e., t ha t  d y n o r p h i n  A 6-13 b locks  the  b r e a k d o w n  o f  
[lZSI]dynorphin A 1-13. Since we were  able  to d e m o n s t r a t e  
only  a sl ight inhibi t ion of  the  b r e a k d o w n  o f  [3H]dynorphin  A 
by d y n o r p h i n  A l -13 ,  it is unc lea r  if this  e n z y m e  is the  same 
e n z y m e  desc r ibed  by Lesl ie  and  Go lds t e in  [20]. H o w e v e r ,  
th is  may  be  due to rapid  b r e a k d o w n  including ca rboxy  ter- 
minal  c leavage  of  d y n o r p h i n  A 1-13. Obv ious ly ,  fu r the r  
s tudies  are neces sa ry  to conf i rm the  ex i s t ence  of  such  an 
e n z y m e ,  bu t  poss ib le  mhlb i to r s  of  this  e n z y m e  could  p r o w d e  
o the r  a v e n u e s  of  a p p r o a c h  to s tudying  the  tn  v l v o  phar-  
macologica l  effects  of  d y n o r p h l n  A. 
We have  inc luded da ta  f rom guinea  pig bra in ,  e v e n  though  
p r e h m m a r y ,  to point  ou t  the re  may  be species  d i f fe rences  m 
the  s tabi l i ty  of  d y n o r p h i n  A unde r  binding cond i t ions  across  
species .  In wew of  the  s lower  b r e a k d o w n  of  d y n o r p h i n  A m 
vto o,  it may  be of  in te res t  to pur sue  a c o m p a r i s o n  of  dynor -  
phln  A and  d y n o r p h i n  A 2-17 effects  in vtvo m gu inea  pigs. 
In conc lus ion ,  m rat ,  it appea r s  tha t  d y n o r p h i n  A is 
rapidly  b r o k e n  d o w n  to d y n o r p h m  A 2-17,  a non-op io id  but  
b e h a w o r a l l y  ac t ive  f r agmen t  of  d y n o r p h m .  The  rapidi ty  of  
this  b r e a k d o w n  m w v o  may expla in  the  difficulty in d e m o n -  
s t ra tmg oplold effects  of  d y n o r p h i n  A m v~vo in th~s species .  
The  large n u m b e r  of  non-op~otd effects  o b s e r v e d  fol lowing m 
vtvo re ject ion of  d y n o r p h i n  A, which  can  be  mimicked  by 
d y n o r p h m  A 2-17,  may  occu r  t h rough  the  c o n v e r s i o n  of  
d y n o r p h m  A to the behav iora l ly  ac t ive  d y n o r p h m  A 2-17 
f r agmen t  
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